Allosteric Site of ACE-2 as a Drug Target for COVID-19

[Image: see text] The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on healthcare systems and our lives. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide protection against SARS-CoV-2. However, mutations in the viral genome are common, rai...

Descripción completa

Detalles Bibliográficos
Autor principal: Dutta, Kunal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864771/
https://www.ncbi.nlm.nih.gov/pubmed/35295933
http://dx.doi.org/10.1021/acsptsci.2c00003
_version_ 1784655520146128896
author Dutta, Kunal
author_facet Dutta, Kunal
author_sort Dutta, Kunal
collection PubMed
description [Image: see text] The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on healthcare systems and our lives. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide protection against SARS-CoV-2. However, mutations in the viral genome are common, raising concerns about the effectiveness of existing vaccines for SARS-CoV-2. The receptor-binding domain (RBD) of SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE-2) as a gateway to enter host cells. Therefore, the ACE-2-RBD interaction may be targeted by antiviral drugs. In this context, allosteric modulation of ACE-2 may offer a promising approach. It may lead to allosteric inhibition of the interaction between ACE-2 and SARS-CoV-2.
format Online
Article
Text
id pubmed-8864771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-88647712022-02-23 Allosteric Site of ACE-2 as a Drug Target for COVID-19 Dutta, Kunal ACS Pharmacol Transl Sci [Image: see text] The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on healthcare systems and our lives. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide protection against SARS-CoV-2. However, mutations in the viral genome are common, raising concerns about the effectiveness of existing vaccines for SARS-CoV-2. The receptor-binding domain (RBD) of SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE-2) as a gateway to enter host cells. Therefore, the ACE-2-RBD interaction may be targeted by antiviral drugs. In this context, allosteric modulation of ACE-2 may offer a promising approach. It may lead to allosteric inhibition of the interaction between ACE-2 and SARS-CoV-2. American Chemical Society 2022-02-14 /pmc/articles/PMC8864771/ /pubmed/35295933 http://dx.doi.org/10.1021/acsptsci.2c00003 Text en © 2022 American Chemical Society https://pubs.acs.org/page/vi/chemistry_coronavirus_researchThis article is made available via the ACS COVID-19 subset (https://pubs.acs.org/page/vi/chemistry_coronavirus_research) for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Dutta, Kunal
Allosteric Site of ACE-2 as a Drug Target for COVID-19
title Allosteric Site of ACE-2 as a Drug Target for COVID-19
title_full Allosteric Site of ACE-2 as a Drug Target for COVID-19
title_fullStr Allosteric Site of ACE-2 as a Drug Target for COVID-19
title_full_unstemmed Allosteric Site of ACE-2 as a Drug Target for COVID-19
title_short Allosteric Site of ACE-2 as a Drug Target for COVID-19
title_sort allosteric site of ace-2 as a drug target for covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864771/
https://www.ncbi.nlm.nih.gov/pubmed/35295933
http://dx.doi.org/10.1021/acsptsci.2c00003
work_keys_str_mv AT duttakunal allostericsiteoface2asadrugtargetforcovid19

Ejemplares similares